SCHEMBL18026252

SCHEMBL18026252

CON(C)C(=O)[C@H]1O[C@@H](n2ccc3c(C)nc(N(C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)nc32)[C@@H]2OC(C)(C)O[C@@H]21

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18009887 0.90 ADORA3 (0.32) —
SCHEMBL18009748 0.89 — —
SCHEMBL18026255 0.87 PRMT5 (0.30) —
SCHEMBL18009857 0.86 PRMT5 (0.33) —
SCHEMBL18026260 0.84 — —
SCHEMBL18026250 0.84 PI4KA (0.39) —
SCHEMBL18026253 0.84 RXFP1 (0.32) —
SCHEMBL18026270 0.83 PRMT5 (0.30) —
SCHEMBL18026254 0.81 PRMT5 (0.31) —
SCHEMBL18009869 0.80 PRMT5 (0.42) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160244475-A1 SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER INC. (US) 2016-08-25 — — US disclosed
Send feedback